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Abstract
Background: Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug
metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of interferon-beta
(IFN-β).
Methods: BxPC-3, CFPAC-1, and Panc-1 cells were pre-treated with IFN-β followed by gemcitabine monotherapy. The
effect on cell growth, colony formation, and cell cycle was determined. RT-qPCR was used to measure gene expression.
BxPC-3 cells were used in a heterotopic subcutaneous mouse model.
Results: IFN-β increased sensitivity to gemcitabine (4-, 7.7-, and 1.7-fold EC50 decrease in BxPC-3, CFPAC-1, and Panc-1,
respectively; all P < 0.001). Findings were confirmed when assessing colony formation. The percentage of cells in the S-
phase was significantly increased after IFN-β treatment only in BxPC-3 and CFPAC-1 by 12 and 7%, respectively (p < 0.001
and p < 0.05, respectively). Thereby, IFN-β upregulated expression of the drug transporters SLC28A1 in BxPC-3 (252%) and
SLC28A3 in BxPC-3 (127%) and CFPAC-1 (223%) (all p< 0.001). In vivo, combination therapy reduced tumor volume with
45% (P = 0.01). Both ex vivo and in vivo data demonstrate a significant reduction in the number of proliferating cells,
whereas apoptosis was increased.
Conclusions: For the first time, we validated the chemosensitising effects of IFN-β when combined with gemcitabine
in vitro, ex vivo, and in vivo. This was driven by cell cycle modulation and associated with an upregulation of genes
involving intracellular uptake of gemcitabine. The use of IFN-β in combination with gemcitabine seems promising in
patients with pancreatic cancer and needs to be further explored.
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Background
Pancreatic cancer is a highly malignant disease, with an es-
timated 5-years survival of 9% [1]. At diagnosis, approxi-
mately 15% of the patients have resectable disease (stage I
or II), which indicates surgery followed by systemic therapy
[2]. The CONKO-001 trial is the first randomized con-
trolled trial in pancreatic cancer that reported longer
overall survival (OS) rates in patients treated with adjuvant
gemcitabine compared with observation alone. However,
the median OS with this regimen is still only 22months
[3]. Recently, Conroy et al. demonstrated a significant
survival benefit with modified FOLFIRINOX compared to
gemcitabine alone (PRODIGE-24 trial) in highly selected
patients [4]. In addition, new chemotherapeutic strategies
in combination with gemcitabine are currently explored
and also improved the prognosis of pancreatic cancer [4,
5]. However, these new regimens are associated with severe
toxicity in comparison with gemcitabine alone. Since the
majority of patients are elderly or have serious comorbidity,
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gemcitabine is often the only therapeutic option. The resist-
ance of this chemotherapeutic is still a major impediment
of successful systemic treatment for patients diagnosed
with pancreatic cancer.
The limited efficacy of gemcitabine has been associ-
ated with impaired drug metabolism, hindering its intra-
cellular uptake and activation [6]. Gemcitabine, 2′,2′-
difluoro 2′-deoxycytidine (dFdC), is a hydrophilic pro-
drug that requires cellular uptake and intracellular phos-
phorylation. Several transporters have been identified,
but its major uptake is through hENT1, hCNT1, and
hCNT3 (encoded by SLC29A1, SLC28A1, and SLC28A3,
respectively) [7]. Expression levels of these transporters
correlate with gemcitabine sensitivity and OS in pancre-
atic cancer, making them good predictive markers [8, 9].
Once inside the cell, gemcitabine requires a serial of
phosphorylation by multiple kinases to become pharma-
cologically active. The cytotoxic activity of gemcitabine is
a result of several inhibitory actions on DNA synthesis. In-
corporation into new DNA strands as the cell replicates is
the most likely mechanism by which gemcitabine causes
cell death. This incorporation creates an irreparable error
(masked chain termination) that leads to inhibition of
DNA synthesis, and thus apoptosis.
Deoxycytidine kinase (dCK) catalyzes the initial and rate-
limiting monophosphorylation of gemcitabine. However,
the majority (~ 90%) of intracellular gemcitabine is directly
inactivated by deamination by cytidine deaminase (CDA) to
form 2′2’ difluorodeoxyuridine (dFdU), which is subse-
quently degraded and excreted out of the cell [7]. Thus, de-
ficiency in dCK is a major contributor to gemcitabine
resistance, while upregulation of CDA has been shown to
confer gemcitabine resistance in pancreatic cancer [10, 11].
Prior studies have proposed a potential role for type I
IFNs (IFN-α and -β) in combination with gemcitabine in
the treatment of pancreatic cancer. IFN-α and -β were ori-
ginally identified as immunomodulatory cytokines, due to
their antiviral activity. Further characterization of their
biological effect revealed a wide range of potential anti-
tumor effects, e.g. inhibition of cell proliferation, induction
of apoptosis, and cell cycle arrest. Importantly, type I IFNs
have been shown to sensitize cancer cells to chemo- and
radiotherapy [12–14].
Both IFN-α and -β interact with the type I IFN recep-
tor complex, which initiates the JAK/STAT downstream
pathway, resulting in subsequent transcription of inter-
feron stimulated genes (ISGs). These ISGs encode for
numerous proteins that initiates different IFN activities,
including anti-tumor effects, immunoregulatory effects,
and other host effects [15].
While prior research has primarily focused on the anti-
tumor activities of IFN-α, studies have reported that the
direct anti-tumor effects of IFN-β are much stronger, and
elicited at much lower concentrations, as compared to
IFN-α [16, 17]. However, there are no animal or clinical
studies that investigated the use of concomitant adjuvant
IFN-β therapy in the treatment of pancreatic cancer.
In the present study, we aimed to further explore the
potential chemosensitising effect of IFN-β and studied the
mechanism of action in three human pancreatic cancer cells
lines. For the first time, we demonstrate the interaction be-
tween IFN-β and the expression of genes involved in gemci-
tabine transport and metabolism. In addition, we evaluated
the effects of IFN-β and gemcitabine in a pancreatic cancer
xenograft tissue slice model. Finally, we confirmed the anti-
tumor effect of IFN-β in combination with gemcitabine in a
heterotopic pancreatic cancer mouse model.
Methods
Cell culture and compounds
Three human pancreatic cancer cell lines (BxPC-3, CFPA
C-1, and Panc-1) were used and obtained from American
Type Culture Collection (Rockville, MD, USA). Short tan-
dem repeat profiling using a Powerplex Kit (Promega, Lei-
den, the Netherlands) of the cells gave consistent results
with the ATCC database. Cells were confirmed as
mycoplasma-free. Culture conditions were described in
detail previously [18]. Human recombinant IFN-β-1a
(Rebif, Rockland, MA, USA) and gemcitabine (Sigma-Al-
drich, Zwijndrecht, the Netherlands) stock solutions, pre-
pared in H2O, were stored at 4 °C. After trypsinization,
cells were plated at the appropriate density in order to ob-
tain 80% confluency at the end of the experiment. The
next day, incubations with the indicated compounds were
initiated and control cells were vehicle treated. For seven-
day experiments, both drug compounds and medium were
refreshed after 3 days. All cell culture experiments were
carried out at least twice in quadruplicate.
Cell proliferation assay
Treatment effects were assessed on DNA amount as
measure of cell number. After treatment, media were re-
moved and plates were stored at − 20 °C until DNA
measurement. Measurement of total DNA was per-
formed with the bisbenzimide fluorescent dye (Hoechst
33258, Sigma-Aldrich, Zwijndrecht, the Netherlands) as
previously described [19].
Colony-forming assay
Plates were coated with 1mL poly-L-lysine (10 μg/mL),
where after 1500, 200, or 300 cells were plated in a 6 wells
plate for BxPC-3, CFPAC-1, and Panc-1, respectively. After
1 day, drug treatment was initiated. After treatment, media
were removed and refreshed without drugs. When colonies
contained at least 50 cells (2 weeks for all cell lines), cells
were washed and stained with haematoxylin. Amount and
size of colonies was measured using MultiImage light cabi-
net (Alpha Innotech) and the ImageJ software. Plating
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efficiency (PE) was calculated as the mean number of
colonies/number of plated cells for control cultures not
exposed to drugs. Surviving fraction was calculated as
the mean number of colonies/(number of inoculated
cells x PE).
Cell cycle analysis
After treatment, cells were harvested, washed with NaCl,
fixed with ice-cold 70% EtOH, and stored at − 20 °C
until analysis. Analyses were performed using the Muse®
Cell Cycle Assay Kit utilizing Muse™ Cell Analyser
(Merck Millipore, Amsterdam, the Netherlands).
Real-time quantitative PCR
Total RNA was isolated using the High Pure RNA Purifi-
cation Kit (Roche). Yield and purity were assessed with
the nanodrop. cDNA was synthesized from mRNA tem-
plate by reversed transcription. To synthesize cDNA, 500
ng mRNA template was added to 40 μL Super RT buffer
(Thermofisher Scientific, the Netherlands) containing 40
nmol dNTP, 20 U RNA’sin, 15 ng oligo-dT, 4 U Super RT.
After 1-h incubation at 40 °C, cDNA was five times di-
luted. 7.5 μL TaqMan Universal PCR Master Mix (Applied
Biosystems) was mixed with concentrations of the used
primers and probes, with 5 μL cDNA template. The RT-
PCR reaction was performed using the 7900HT Fast Real-
Time PCR System. Three housekeeping genes (HPRT, β-
actin, and GUSB) were used to normalize mRNA levels
using the Vandesompele method (Thermo Fisher Scien-
tific, Breda, the Netherlands) (Table S1) [20].
Animals and heterotopic injection of BxPC-3 tumor cells
Male athymic Balb/C nude mice (commercially obtained
from Harlan laboratories, UK ltd) of 8 weeks old, were used
and kept in a barrier facility under HEPA filtration. BxPC-3
cells (1 × 106/100 μl PBS) were subcutaneously injected at
the flank after which the mice were randomized into four
groups (n = 8 each). A separate group (n = 4), which did not
receive any treatment, was used for tissue slice experiments.
All mouse experiments were controlled by the animal wel-
fare committee (IvD) of the Erasmus Medical Center and
approved by the national central committee of animal ex-
periments (CCD) under the protocol number 105–12-52,
in accordance with the Dutch Act on Animal Experimenta-
tion and EU Directive 2010/63/EU.
Therapy and assessment of tumor size
Tumor size and body weight was measured twice weekly.
Tumor volumes were calculated as (lengthxwidth)1.5x(π/
6). Treatment was started when tumor volumes reached
~150mm3. Mice in the control group and IFN-β group re-
ceived five times a week, on consecutive days, an i.p. injec-
tion of 100 μl of 0.9% NaCl or 1.5 × 105 IU of IFN-β. Mice
in the gemcitabine group received on day 2 and 4 40mg/
kg gemcitabine i.p. Mice in the combination group
recieved five times a week, on consecutive days, an injec-
tion of 1.5 × 105 IU of IFN-β i.p. and, on day 2 and 4, an
40mg/kg gemcitabine i.p.
Necropsy procedures
Mice were sacrificed by cervical dislocation under iso-
flurane anesthesia after 4 weeks of treatment, when
tumor volume reached 2000mm3 (1500mm3 for tumors
of mice used in the tissue slice experiments), or when
the wellbeing (i.e. weight loss, lethargy, tumor ulcer-
ation) of the mice could no longer be maintained.
During necropsy, tumors were resected and tumor
weight and volume were measured. Tumors were di-
vided into three parts and subsequently snap frozen in
liquid nitrogen, embedded in Tissue-Tek (Sakura Fine-
tek, Zoeterwoude, the Netherlands) for cryosectioning
and fixed in freshly prepared 4% formaldehyde solution,
and prepared for paraffin sectioning. Tumors were
harvested, weighted and fixed in 4% formaldehyde.
Tissue slicing and slice culture
When tumors reached a volume of 1500mm3, mice were
sacrificed and necropsy was performed as described above.
After resection, tumors were washed twice with Hanks’
Balanced Salt Solution (HBSS) supplemented with penicil-
lin (1 × 105 U/L), streptomycin (1000 IU/ml) and fungi-
zone (30 μg/ml).
After the vibrocheck (measurement of vertical deflec-
tion) was performed, tumor specimens, buffered in ice-
cold HBSS, were cut, with stainless steel razor blades,
into slices of 200 μm using the Leica vibrating blade
microtome VT1000 S (Leica, Wetzlar, Germany). After
slicing, samples were washed once more and trans-
ferred into six-well multiplates containing 5 ml of cul-
ture medium consisting of Dulbecco’s Modified Eagle’s
Medium: nutrient mixture F-12 (DMEM/F-12), supple-
mented with penicillin (1 × 105 U/L), streptomycin
(1000 IU/ml) and 10% FCS. Consecutive slices were
used for the experiments (minimum of 15 slices per
tumor).
Tissue culture plates were placed in a humidified incu-
bator at 5% CO2 and continuously shaken (60 rounds/
min) at 37 °C up to 4 days post slicing. Media and sup-
plements were obtained from GIBCO Bio-cult Europe
(Invitrogen, Breda, The Netherlands). After 24 h, media
were refreshed and slices were incubated with IFN-β
(100 IU/ml), gemcitabine (1 ng/ml), or with the combin-
ation of IFN-β and gemcitabine. After 72 h of incuba-
tion, tissue slices were harvested fixed in freshly
prepared 4% formaldehyde solution and prepared (in up-
right position) for standard paraffin sectioning.
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Immunohistochemistry
The formalin fixed and paraffin embedded sections (5 μm
thick) were treated for immunohistochemistry as de-
scribed previously [21]. Briefly, sections were deparaffi-
nised and rehydrated, followed by heat induced epitope
retrieval, rinsed (TRIS/Tween 0.5% (pH 8.0)) and blocked
(hydrogen peroxide 3% in PBS) for 15min before incuba-
tion with the primary antibodies for Caspase-3 and Ki-67
(both overnight at 4 °C). For negative controls, the primary
antibody was omitted. The Dako Real EnVision Detection
System kit (Dako Detection System, Dako Denmark,
Glostrup, Denmark) was used to visualize the bound anti-
body after which the slides were counterstained with
haematoxylin and coverslipped. The rabbit monoclonal
Cleaved Caspase-3 (Asp175) antibody (cell signalling tech-
nology, Beverly, MA, USA) was used at a dilution of 1:750.
The mouse monoclonal Ki-67 antibody (Dako Detection
System) was used at a dilution of 1:400.
Immunohistochemical analysis
All sections were evaluated and counted by AB using Cell-
Profiler (cell image analysis software) [22]. Apoptosis and
cell proliferation were assessed by counting the total num-
ber of caspase-3 or Ki-67 positive tumor cells per high-
power field (Olympus, Nikon Eclipse E400, HPF × 40 ob-
jective). For the analysis, a minimum of 3 HPF were used
to evaluate cells with a positive and negative staining.
Statistical analysis
GraphPad Prism version 3.0 (GraphPad Software) was
used for statistical analysis. Non-linear regression curves
were used to calculate the half maximal effective con-
centration (EC50) on cell growth. For analysis of the
combination therapy, effect of IFN-β was set on 100%
and used as control. One-way ANOVA test with Tukey’s
multiple comparisons test was used for comparisons
among treatment groups. Regarding in vivo experiments,
differences between groups were evaluated by the
Mann-Whitney t-test. In all analyses, values of p < 0.05
were considered as significant. Data are indicated as
mean ± SEM, unless specified otherwise.
Results
IFN-β and gemcitabine dose-dependently inhibit
proliferation in human pancreatic cancer cells
To assess the growth inhibitory effect of IFN-β and gemci-
tabine, cells were treated with increasing concentrations
(10–10.000 IU/ml) IFN-β or (0.1–5 ng/ml) gemcitabine
during 3 or 7 days. Both drugs inhibited cell growth, mea-
sured as DNA amount per well, in a dose- and time
dependent manner (Fig. 1a and S1).
After 7 days, IFN-β inhibited cell growth in BxPC-3 at
significantly lower concentrations (EC50 62 IU/ml; 95% CI
7.4–66.4) than CFPAC-1 (302 IU/ml; 95% CI 285.6–319.5;
p < 0.001) and Panc-1 (978 IU/ml; 95% CI 896.8–1067;
p < 0.001). For gemcitabine, EC50 value after 7 days was
lower for CFPAC-1 (0.19 ng/ml; 95% CI 0.17–0.2), com-
pared to BxPC-3 (0.81 ng/ml; 95% CI 0.79–0.84; p < 0.001)
and Panc-1 (1.0 ng/ml; 95% CI 0.98–1.02; p < 0.001).
Time-dependent upregulation of expression of interferon-
stimulated genes by IFN-β
Gene expression analysis of three ISGs (IFIT1, OAS1A,
and Mx1) was performed after cells were treated for 4,
12, 24 or 72 h with 100 IU/ml (BxPC-3 and CFPAC-1)
or 1000 IU/ml (Panc-1) IFN-β. The average baseline ex-
pression of all three genes was higher in BxPC-3 and
CFPAC-1, compared to Panc-1 (Fig. 1b, upper panel).
All genes were upregulated during IFN-β treatment in
a time-dependent manner (Fig. 1b, lower panel). The
strongest induction was observed in Mx1 after 72 h
treatment. In BxPC-3 and CFPAC-1, Mx1 expression
was already significantly upregulated after 4 h treatment
with IFN-β. In Panc-1, a significant lower increase of all
three genes was observed, even though cells were treated
with 1000 IU/ml IFN-β.
IFN-β sensitizes pancreatic cancer cells to gemcitabine
treatment
Next, we assessed the potential chemosensitising effect of
IFN-β, as indicated by a fold decrease in EC50 value of
gemcitabine. Cells were pre-treated for 4, 12, 24 or 72 h
with 100 IU/ml (BxPC-3 and CFPAC-1) or 1000 IU/ml
(Panc-1) IFN-β, followed by 3 days of increasing concen-
trations (0.1–5 ng/ml) gemcitabine monotherapy (Fig. 1c).
The overall response to gemcitabine was significantly
stronger in IFN-β pre-treated cells compared to un-
treated control cells, even at time points where the effect
of IFN-β on cell growth was minimal (Fig. S2).
This chemosensitising effect was most evident when
cells were pre-treated for 72 h with IFN-β, as shown by a
4-, 7.7-, and 1.7-fold decrease in EC50 value in BxPC-3,
CFPAC-1, and Panc-1 respectively (all P < 0.001 vs un-
treated control cells). Strikingly, in BxPC-3 and CFPAC-
1, 4 h IFN-β pre-treatment resulted already at low con-
centrations gemcitabine (up to 0.1 ng/ml) in a significant
higher cell growth inhibition (1.9- and 1.8-fold lower
EC50 value respectively, both p < 0.001 vs untreated con-
trol cells) (Fig. 1d and Fig. S2).
An additional experiment was performed, in which
cells were treated with simultaneously 100 IU/ml (BxPC-
3 and CFPAC-1) or 1000 IU/ml (Panc-1) IFN-β plus in-
creasing concentrations (0.5–5 ng/ml) gemcitabine for 3
days. In this experimental setting, the overall response of
gemcitabine was not significantly stronger compared to
cells without IFN-β treatment (Fig. S3).
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IFN-β potentiates the anti-tumor effects of gemcitabine
on colony formation
Effect on mean colony size and surviving fraction was
assessed after 72 h IFN-β (100 IU/ml for BxPC-3 and
CFPAC-1; 1000 IU/ml for Panc-1), after 72 h gemcitabine,
and after 72 h IFN-β pre-treatment followed by 72 h gem-
citabine monotherapy. Two concentrations gemcitabine
were used, in which a minimal effect on cell growth was
observed at monolayer culture (1 and 2.5 ng/ml for BxPC-
3 and Panc-1; 0.1 and 1 ng/ml for CFPAC-1). PE (%) for
BxPC-3, CFPAC-1, and Panc-1 were 19 ± 2.8, 78 ± 18, and
24 ± 7 respectively.
IFN-β reduced the mean colony size in BxPC-3 and low-
ered the survival fraction in CFPAC-1 (40 and 44% respect-
ively, both p < 0.001). While no effect on survival fraction
was observed, IFN-β pre-treatment enhanced the cytotoxic
effect of gemcitabine in BxPC-3 (p < 0.001). Moreover, the
cytostatic effect of gemcitabine was increased in CFPAC-1
Fig. 1 In vitro treatment effects of gemcitabine and IFN-β. a Dose response curves of gemcitabine and IFN-β on total DNA amount, as a measure of cell
number, in ● BxPC-3, ■ CFPAC-1, and▲ Panc-1 after 7 days of treatment. b Upper panel represents baseline mRNA expression of IFIT1, OAS1A, and Mx1 in
BxPC-3 (left panel), CFPAC-1 (middle panel), and Panc-1 (right panel); Lower panel represent relative mRNA expression in untreated control cells and after 4
(white bar), 12 (light grey bar), 24 (dark grey bar), or 72 h (black bar) pre-treatment with IFN-β. c Experimental design for in vitro experiments. Cell were pre-
treated with IFN-β for 4, 12, 24 or 72 h, followed by 72 h gemcitabine monotherapy. d EC50 values of gemcitabine on cell growth in non-IFN-β pre-treated
cells vs IFN-β pre-treated cells. EC50 values are presented in nanogram per milliliter (ng/ml, 95% CI). EC50 values depicted in bold represent the strongest
decrease. Used concentrations IFN-β: 100 IU/ml for BxPC-3 and CFPAC-1, and 1000 IU/ml for Panc-1. Values represent mean ± SEM of at least two
independent experiments in quadruplicate and are shown as the percentage of control. *p< 0.05, **p< 0.01, and ***p< 0.001 versus control
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and Panc-1 due to IFN-β pre-treatment (both p < 0.001)
(Fig. 2).
IFN-β accumulates the proportion of cells in the S-phase
Cell cycle analysis was performed after 72 h IFN-β (100
IU/ml for BxPC-3 and CFPAC-1; 1000 IU/ml for Panc-
1), after 72 h gemcitabine (1 ng/ml for CFPAC-1; 2.5 ng/
ml for BxPC-3 and Panc-1), and after 72 h IFN-β pre-
treatment followed by 72 h gemcitabine monotherapy.
IFN-β increased the percentage of cells in the S-phase in
BxCP-3 (12%, p < 0.001) and CFPAC-1 (7%, p < 0.05)
(Fig. 3). Additionally, an increase of S-phase population
Fig. 2 Colony-forming assay. a Cytostatic and cytotoxic analysis of colonies in BxPC-3 (left panel), CFPAC-1 (middle panel), and Panc-1 (right
panel). Upper panel represents the effect of 72 h IFN-β monotherapy on surviving fraction and colony size. Middle and lower panel represent the
effect of 72 h gemcitabine (GEM) in untreated control cells (white bar) versus 72 h IFN-β pre-treated cells (black bar) on surviving fraction and
colony size. Used concentrations IFN-β: 100 IU/ml for BxPC-3 and CFPAC-1, and 1000 IU/ml for Panc-1. Used concentrations gemcitabine: 0.5–1
ng/ml for CFPAC-1; and 1–2.5 ng/ml for BxCP-3 and Panc-1. Data are presented as percentage of vehicle treated control. For IFN-β pre-treated
cells, effect of IFN-β was set on 100% and used as control. b Photomicrographs of treatment effects on BxPC-3 colonies. Red stained colonies
represent the measured colonies. Based on cut-off values for number and size, black stained colonies were excluded. Values represent mean ±
SEM of at least two independent experiments and are shown as a percentage of control. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control
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was observed after gemcitabine treatment in CFPAC-1
and Panc-1, which was associated with a decrease of cells
in the G0/G1-phase (27 and 19% respectively, both p <
0.001). In BxPC-3, treatment with gemcitabine caused a
minimal decrease of cells in the S-phase (− 4%, p < 0.01).
IFN-β pre-treatment followed by gemcitabine resulted in
the strongest S-phase accumulation, with an increase of 33,
42, and 29% in BxPC-3, CFPAC-1, and Panc-1, respectively
(all p < 0.001). This S-phase accumulation was associated
with a strong decrease of cells in the G0/G1−phase (BxPC-3,
28%; CFPAC-1, 35%; Panc-1, 33%; all p < 0.001).
IFN-β upregulates expression of transporter genes
involving the intracellular uptake of gemcitabine
As illustrated in Fig. 4a, several genes are involved in the
metabolic pathway of gemcitabine. Gene expression ana-
lysis was performed of all genes after 72 h IFN-β (100 IU/
ml for BxPC-3 and CFPAC-1; 1000 IU/ml for Panc-1).
Baseline expression of SLC28A1 and SLC28A3 was low (<
0.0001) in BxPC-3 and CFPAC-1, and not detectable in
Panc-1 (Fig. S3). IFN-β strongly increased SLC28A1 and
SLC28A3 in BxPC-3 by 252 and 127%, respectively (both
p < 0.001). In CFPAC-1, SLC28A3 was upregulated by
223% (p < 0.001). Remarkably, no increase in the expression
of these genes was observed in Panc-1. Regarding the in-
activating genes, IFN-β increased expression of CDA in
BxPC-3 and Panc-1 (21 and 78% respectively, both p <
0.001). Expression of NT5E was increased in all cell lines
(BxPC-3, 64% p < 0.001; CFPAC-1, 34% p < 0.001; Panc-1,
17% p < 0.01). No difference in expression of the activating
genes was observed (Fig. 4b).
Ex vivo prevalidation of IFN-β mono- and combination
therapy
In order to attempt to use a model that might predict
treatment effects in vivo, an ex vivo precision cut tissue
slice model was used. Four xenograft tumors of un-
treated mice were used to create the tissue slices. Slices
were incubated for 72 h with 100 IU/ml IFN-β, 1 ng/ml
gemcitabine, or the combination of IFN-β plus gemcita-
bine (Fig. 5a).
We next examined the expression of the cell prolifera-
tion marker Ki-67 and the apoptosis maker Caspase-3 in
tumor tissue slices. The proportion of Ki-67 positive cells
was significantly reduced after IFN-β, gemcitabine, and
after the combination of IFN-β plus gemcitabine (decrease
of 34, 43, and 50% respectively; all P < 0.01). Additionally,
combination therapy significantly increased the number of
apoptotic cells (increase of 85%, P = 0.02) (Fig. 5b and c).
In vivo validation of IFN-β mono- and combination
therapy using a subcutaneous pancreatic cancer model
Finally, we examined the effects of IFN-β and gemcitabine,
alone or in combination, on the growth of pancreatic tu-
mors in nude mice. BxPC-3 cells were subcutaneously
injected into male Balb/C mice. After 1 week, mice were
randomized into one of four treatment arms: vehicle
(NaCl), IFN-β (1.5 × 105 IU), gemcitabine (40mg/kg) or
both agents combined (Fig. 6a).
The time course of the growth of tumor volume is
depicted in Fig. 6b. After 4 weeks of treatment, a signifi-
cant reduction in tumor volume by 45% was found com-
pared to untreated mice (P = 0.01). No significant weight
loss was observed in any of the treatment groups, indicat-
ing that all the treatments were well tolerated (Table 1).
However, in the gemcitabine arm, one mouse was found
dead before start of the treatment and one mouse at the
end of the total treatment cycle. Due to organ and tumor
lysis, necropsy was not possible anymore.
As observed ex vivo in the tissue slice experiments, the
combination of IFN-β plus gemcitabine significantly re-
duced the proportion of Ki-67 positive cells with 44%, while
Fig. 3 Cell cycle analysis. Cell cycle distribution in BxPC-3 (left panel), CFPAC-1 (middle panel), and Panc-1 (right panel) after 72 h IFN-β, 72 h gemcitabine,
and after 72 h IFN-β pre-treatment followed by 72 h gemcitabine monotherapy. Used concentrations IFN-β: 100 IU/ml for BxPC-3 and CFPAC-1, and 1000
IU/ml for Panc-1. Used concentrations gemcitabine: 1 ng/ml for CFPAC-1 and 2.5 ng/ml for BxPC-3 and Panc-1. Values represent mean ± SEM of at least
two independent experiments and are shown as relative percentage of the total cell population. *p< 0.05, **p< 0.01, and ***p< 0.001 versus control
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Fig. 4 mRNA expression of genes involved in transport and metabolism of gemcitabine in BxPC-3 (upper panel), CFPAC-1 (middle panel), and
Panc-1 (lower panel). a Schematic overview of the genes encoding for the transporters (SLC29A1, SLC28A1, and SLC28A3), activating enzymes (dCK,
CMPK1, and NME1), and inactivating enzymes (CDA, NT5E, and DCTD) of gemcitabine. b Percentage change in mRNA expression between
untreated control cells (white bars) and after 72 h IFN-β (coloured bars). Used concentrations IFN-β: 100 IU/ml for BxPC-3 and CFPAC-1, and 1000
IU/ml for Panc-1. Values represent mean ± SEM of at least two independent experiments in quadruplicate and are shown as a percentage of
control. **p < 0.01 and ***p < 0.001 versus control
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Fig. 5 Effects of IFN-β and gemcitabine using an ex vivo precision cut tissue slice model. a Experimental design for ex vivo experiments. Slices,
derived from xenograft BxPC-3 tumors of untreated mice, were incubated for 72 h without or with IFN-β (100 IU/ml), gemcitabine (1 ng/ml), or
the combination of IFN-β plus gemcitabine. b Representative tissue slides of human pancreatic cancer xenograft tissue slices stained for KI-67
(upper panel) or caspase-3 (lower panel) in control and treated slices. c Immunohistochemical analysis of Ki-67 (left) and cleaved caspase-3 (right)
expression, representing the proportion of proliferating cells and the proportion of apoptotic cells respectively. Values represent mean ± SEM of at
least three different areas within the tumor and are shown as a percentage of control. **p < 0.01 and ***p < 0.001 versus control
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Fig. 6 Treatment effects of IFN-β and gemcitabine in a subcutaneous heterotopic human pancreatic cancer model. a Experimental design for
in vivo experiments. BxPC-3 human pancreatic cancer cells (1 × 106 /100 μl PBS) were subcutaneously injected in nude mice. Seven day later,
groups of mice received five times a week, on consecutive days, an i.p. injection of IFN-β (1.5 × 105 IU), two times a week (at day 2 and 4) an i.p.
injection of gemcitabine (40 mg/kg), or the combination of IFN-β plus gemcitabine. Mice in the control group received five times a week, on
consecutive days, an intraperitoneal (i.p.) injection of 100 μl of 0.9% NaCL. b Time course of change in tumor volume (left). After 4 weeks of
treatment, mice were sacrificed and tumor volume was measured (right). c Photomicrographs of representative tissue slides of
immunohistochemical staining for Ki-67 or cleaved caspase-3, d Immunohistochemical analysis of Ki-67 (left) and cleaved caspase-3 (right)
expression, representing the proportion of proliferating cells and the proportion of apoptotic cells respectively. Values represent mean ± SEM of at
least three different areas within the tumor and are shown as a percentage of control. **p < 0.01 and ***p < 0.001 versus control
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apoptosis was increased with 168% in tumor tissues com-
pared with control group (both P < 0.05) (Fig. 6c and d).
Discussion
So far, gemcitabine has demonstrated disappointing re-
sults in patients with pancreatic cancer. More effective
chemotherapeutics like FOLFIRINOX, where chemore-
sistance also remains a major clinical problem, is associ-
ated with frequent dose reductions, treatment-related
serious adverse events, and often grade 3–4 infections.
Since gemcitabine is much better tolerated with less tox-
icity compared to the newer chemotherapeutic agents,
especially in the elderly pancreatic cancer patients, we
aimed to evaluate whether the anti-tumor effect of gem-
citabine could be enhanced by IFN-β and to demon-
strate the mechanism of action.
First, we studied the effect of IFN-β alone and in com-
bination with gemcitabine in three human pancreatic can-
cer cell lines: two IFN-β sensitive cell lines (BxPC-3 and
CFPAC-1) and an IFN-β insensitive cell line (Panc-1) [16].
IFN-β strongly increased the inhibitory effects of gemcita-
bine in the IFN-β sensitive cell lines, which was confirmed
in colony-forming assay. Both the cytotoxic and cytostatic
effects of gemcitabine were significantly enhanced by IFN-β.
The increased chemosensitivity can be explained by two
important observations. First, IFN-β increased cell popula-
tion in the S-phase, suggesting that these cells were not
able to transit into the G2/M-phase efficiently, and there-
fore exhibited a prolonged stay in the S-phase. As a result,
DNA replication fails and cells can become more vulner-
able for gemcitabine treatment. A downregulation and im-
paired activity of cyclins and cyclin dependent kinases was
previously reported after IFN-β treatment, explaining the
prolonged stay in the S-phase [23]. The active metabolites
of gemcitabine, dFdCDP and dFdCTP, are also known to
inhibit DNA synthesis by inhibiting ribonucleotide reduc-
tase and by DNA incorporation, respectively. Conse-
quently, a complete inhibition of DNA synthesis is
achieved, and apoptosis is induced [7]. Combination ther-
apy with IFN-β and gemcitabine resulted in the strongest
induction of cells in the S-phase in the IFN-β sensitive cell
lines. In Panc-1, no difference was observed upon IFN-β
treatment, which is in line with the absence of the chemo-
sensitising effect in this cell line.
The second observation is the upregulation of gemci-
tabine transporters by IFN-β, resulting in potentially in-
creased drug influx. A strong correlation was found
between treatment resistance and the expression of gem-
citabine transporters (hENT1, hCNT1, and hCNT3), ac-
tivating enzyme (dCK), and inactivating enzyme (CDA)
of gemcitabine [6, 7]. It should be emphasized, however,
that we studied the effect of IFN-β on mRNA expression
of gemcitabine transporters only. Further studies are ne-
cessary to demonstrate that IFN-β treatment results in
increased intracellular gemcitabine levels and to confirm
this mechanism of action by e.g. transporter knockdown.
Nevertheless, this is the first study that evaluated the po-
tential interaction between IFN-β and the expression of
genes involved in gemcitabine transport and metabolism
of gemcitabine. IFN-β strongly increased the expression
of genes encoding for the hCNT1 and hCNT3 trans-
porter in BxPC-3 and CFPAC-1. In contrast, IFN-β up-
regulated expression of CDA in Panc-1 cells.
The time of incubation with IFN-β appeared to be a
significant parameter in our study. First, the (chemosen-
sitising) anti-tumor effect was time-dependent. Notably,
a 4 h pre-treatment with IFN-β already increased the re-
sponse to gemcitabine in the IFN-β sensitive cell lines.
In line with this, expression of ISGs was upregulated
after 4 h and increased over time. Secondly, IFN-β did
not enhance the gemcitabine response when both drugs
were given simultaneously, suggesting that IFN-β needs
time to sensitize tumor cells for chemotherapy.
Remarkably, there were significant differences between
the IFN-β sensitive cell lines BxPC-3 and CFPAC-1 and
the relative insensitive cell line Panc-1. First, the anti-
tumor effects of IFN-β were less pronounced in Panc-1,
even though these cells were treated with a 10-fold
higher concentration (1000 IU/ml). Thereby, IFN-β pre-
treatment mainly resulted in an additive anti-tumor
effect in monolayer culture. Surprisingly, while IFN-β
monotherapy had no effect on the colony size, it signifi-
cantly enhanced the effect of gemcitabine on the colony
size, suggesting a synergistic effect.
Table 1 Treatment of subcutaneous heterotopic human pancreatic BxPC-3 tumors in nude mice
Treatment groups Completion
of
treatment
Tumor volume (mm3) Tumor weight (g) Body weight (g)
Mean Range Mean Range Mean Range
Control 5/8a 816 524–999 596 373–790 26 24–28
IFN-β 7/8a 660 281–1370 507 161–852 26 24–28
Gemcitabine 5/7a + b 745 402–1187 628 166–1121 25 24–27
IFN-β + gemcitabine 6/8 447c 213–572 492 161–958 26 24–28
a Number of mice that completed 4 weeks of treatment. Mice were sacrificed before the end of treatment if the wellbeing of the animal could not be maintained
(in all these mice this was due to ulceration of the tumor)
b One mice died before the start of the treatment
c P < 0.05 versus control
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So far, there are no biomarkers for monitoring IFN ac-
tivity and predicting clinical efficacy during IFN-β treat-
ment. Booy et al. studied the correlation between the
expression of the type I interferon receptor and the anti-
tumor effect in a large panel of human pancreatic cancer
cells. Despite the variable receptor expression among the
cell lines, no significant correlation was reported regard-
ing the maximal inhibitory effect of IFN-β [16]. Poten-
tially, the downstream pathway of IFN can predict the
response toward IFN-β treatment. In the current study,
we measured the expression level of three ISGs (Mx1,
IFIT1, and OAS1A), which are the functional end prod-
ucts of the IFN signalling pathway [24]. Therefore, their
expression is induced as a result of an active IFN path-
way. Consequently, expression levels of these ISGs can
be assumed as a representation of activeness of the IFN
pathway. At baseline, highest expression was observed in
BxPC-3 and CFPAC-1, which is in line with the IFN-β
sensitivity. IFN-β upregulated expression of these ISGs
in all three cell lines. However, a much stronger upregu-
lation was observed in BxPC-3 and CFPAC-1 compared
to Panc-1, suggesting a less active IFN pathway in Panc-
1, which might explain the lower response to IFN-β.
Expression ofMx1 was significant higher (approximately
13-fold) in the IFN-β sensitive cell lines compared to
Panc-1, and strongly increased upon IFN-β treatment.
TheMx1 gene encodes for the myxovirus resistant protein
A (MxA) protein, which is an important antiviral factor
against a wide spectrum of RNA viruses [25]. Apart from
its role as a prominent antiviral protein in innate immun-
ity, studies have indicated a role for Mx1 as a potential
tumor suppressor gene. For example, deletion of Mx1 in
prostate cancer is associated with a higher aggressive ten-
dency and the expression of MxA is suppressed in a highly
metastatic human prostate carcinoma cell line [26, 27].
Importantly, MxA is also employed to predict the efficacy
of chemotherapy in several cancers. Knockout of Mx1 in
prostate cancer cells resulted in a lower sensitivity to the
chemotherapeutic agent docetaxel compared to MxA-
positive cells [28]. Additionally, a study by Sistigu et al. re-
ported a benefit of high MxA expression in patients with
breast cancer receiving anthracycline-based chemotherapy
[29]. Above findings indicate an important role for Mx1 in
predicting the response to IFN-β treatment, as well as the
potential chemosensitising effects.
So far, the effects of IFN-β, alone and combined with
gemcitabine, have not been studied in animal models. By
using a heterotopic subcutaneous pancreatic cancer
mouse model, we are the first that confirmed the chemo-
sensitising effect of IFN-β in vivo. Based on the response
to IFN-β and the amount of IFN receptors expressed, we
used the BxPC-3 cells for in vivo experiments [16].
First, we aimed to predict therapy response before
start of treatment in an ex vivo tissue slice model. The
advantage of this model is the ability to evaluate multiple
treatments in one tumor sample. We were able to main-
tain viable slices up to 4 days of culture, which is in
agreement with findings of two other studies [30, 31].
Promising results were observed as the combination of
IFN-β plus gemcitabine significantly reduced the propor-
tion of Ki-67 positive cells, while apoptosis was in-
creased in tumor tissues compared with control group.
Regarding in vivo research, the most frequently used
gemcitabine concentration varies between 100mg/kg and
125mg/kg [32, 33]. Nevertheless, based on the previously
described in vitro findings, we decided to reduce the gem-
citabine concentration and used a suboptimal concentra-
tion of 40mg/kg.
As expected, given this suboptimal treatment dose, no
significant decrease of tumor volume or weight was found
in mice treated with gemcitabine alone. Additionally, des-
pite the potent anti-tumor effects in vitro, no difference
was found in mice treated with IFN-β alone, however,
there was a clear trend towards a smaller tumor volume.
Although IFN-β concentrations were not measured in this
study, it may be possible that the circulating concentration
of IFN-β was not sufficient. This may be related to the
relatively short half-life of IFNs in the circulation [34]. In
vitro, the concentration of IFN-β required to reduce cell
growth to 50% in a large series of pancreatic cancer cell
lines, ranged between 70 and 1000 IU/ml [16]. These con-
centrations are not easily reached (4–10 IU/ml after four
doses of 18 MIU IFN-β at 48-h intervals in serum of
human healthy volunteers after s.c. administration) [34].
Furthermore, the anti-tumor activities of type I IFNs can
be limited by the activation of several survival pathways,
such as the induction of the JAK2/STAT-3 pathway, the
activation of nuclear factor kappa-beta (NF-κB) and the
increased expression of the epidermal growth factor
receptor (EGF-R). This could result in the stimulation of
cell proliferation, malignant transformation and invasion,
and the inhibition of apoptosis [35, 36].
After 30 days of treatment, we observed a significant
synergistic effect of the combined therapy of IFN-β and
gemcitabine, which was reflected by the reduction of
tumor volume and, additionally, by a decreased propor-
tion of proliferating tumor cells and increased apoptosis,
confirming the results observed ex vivo.
Although heterotopic subcutaneous models are often
used in cancer research, it is important to evaluate the
effects of IFN-β and gemcitabine in an orthotopic model
as well. Especially since type I IFNs are known to induce
immunoregulatory activities and interact with the tumor
microenvironment [37].
The therapeutic effectiveness of type I IFN treatment has
been demonstrated in a considerable number of other ma-
lignancies, including hematologic tumors, as well as solid
tumors. However, despite FDA approvals for recombinant
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IFN-α in a few cancers, including melanoma and renal cell
carcinoma, recombinant IFN-α is not a conventional treat-
ment for these malignancies. Long-term administration is
needed to maintain therapeutic efficacy, resulting in high-
grade toxicity and significant adverse side effects in patients
[38].
On the other hand, IFN-β has emerged as a safer and
more potent treatment compared to IFN-α. In addition
to pancreatic cancer, IFN-β induced evident anti-tumor
and chemosensitising effects pre-clinically in several
other cancer types, e.g. hepatocellular carcinoma and
breast cancer [39, 40]. Thereby, studies report chemo-
sensitising effects with other chemotherapeutic agents,
e.g. 5-FU and cisplatin, as well, suggesting that the sensi-
tising effect of IFN-β is not only limited to gemcitabine
[39, 41]. Interesting, the intracellular uptake of these
drugs are also mediated by the nucleotide transporter
proteins hENT1, hCNT1, and hCNT3 [42, 43].
So far, recombinant IFN-β has not yet been approved
for the treatment of any cancer type and has yet to be
clinically tested in pancreatic cancer. In addition, it is
recommended to study the combination of IFN-β with
the new developed chemotherapeutic agents such as
FOLFIRINOX and Nab-Paclitaxel as well.
While IFN therapies have been around for a while, new
insights in activation of the IFN pathway have resulted in
novel IFN-directed cancer treatment strategies. One ex-
ample is the use of IFN based conjugates, which increase
the half-life time of IFN and potentially results into higher
concentrations at the tumor site [44]. In addition, the
PEGylated form of IFN resulted in a higher serum concen-
tration, requiring lower and less frequent doses compared
to the conventional IFNs [45]. The PEGylated form of
IFN-α has already proven to be effective in the treatment
of melanoma and metastatic renal cell carcinoma patients
[46, 47]. Currently, the PEGylated form IFN-β is being
tested in a phase III clinical trial (ADVANCE) in patients
with multiple sclerosis [48, 49]. Another novel approach is
the induction of type I IFN production via activation of
the STING and RIG-I pathway [44]. These approaches are
currently being tested in clinical trials or are in late pre-
clinical development.
Although currently no improvement has been made
with immunotherapy in pancreatic cancer, IFN-β might
also play a crucial role in new strategies in combination
with immunotherapy. Expression of Interferon-stimulated
gene 15 (ISG15) is induced by IFN-β and its pathway is
highly expressed in various malignancies, including pan-
creatic ductal adenocarcinoma. Interestingly Burke et al.
demonstrated that ISG15 pathway knockdown not only
reversed the KRAS-associated phenotypes of pancreatic
ductal adenocarcinoma cells, such as increased prolifera-
tion and colony formation, but also decreased tumor pro-
grammed death ligand-1 (PDL-1) expression leading to
increased number of CD8+ tumor-infiltrating lympho-
cytes [50].
Conclusions
In conclusion, to the best of our knowledge, this is the
first study that determined the effects of IFN-β alone
and in combination with gemcitabine on pancreatic can-
cer in three different experimental models. A synergistic
anti-tumor effect of the combination treatment with
IFN-β and gemcitabine was observed in vitro, in vivo,
and ex vivo. These anti-tumor effects were already
present at low concentrations of gemcitabine and involve
cell cycle modulation and upregulation of gemcitabine
transporters genes by IFN-β. In order to demonstrate
the potent anti-tumor activities of combined gemcita-
bine/IFN-β therapy in the clinical setting, prospective
studies are necessary.
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